New drug trial aims to beat exhaustion from Tick-Borne disease
NCT ID NCT06656351
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tests the drug tafenoquine in 40 adults with chronic babesiosis who have severe fatigue. The goal is to see if tafenoquine can reduce fatigue and clear the Babesia parasite from the blood. Participants take the drug and report their fatigue levels using a standard questionnaire.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tafenoquine
- What this could lead to
- If it works, this could provide a treatment option for chronic babesiosis patients suffering from severe fatigue.
- What could go wrong
- This is a small, early-phase trial with only 40 participants and no placebo group, so results may not be conclusive. The drug may not improve fatigue or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC BABESIOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States